New cobas(R) 4800 System designed to increase laboratory efficiency and medical value Roche Diagnostics Canada (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new Health Canada approved ...

The FINANCIAL — Roche announced on November 3 the commercial availability of the cobas HIV-1, HCV and HCV Genotyping (GT) assays in countries accepting the CE mark. These new molecular diagnostic ...

PLEASANTON, California, Dec. 22, 2015 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of the cobas® HBVassay for use on the cobas®4800 System in ...

PLEASANTON, Calif., Feb. 13, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA clearance for the cobas® Factor II and Factor V Test for use on the cobas® ...

- CMV is the most common and serious viral infection in transplant patients - The cobas® CMV test provides reliable, reproducible, high-quality results for clinical decision-making - CMV viral load ...

PLEASANTON, Calif., Dec. 9 Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency ...

Roche announced last week that it received FDA 510(k) clearance for the cobas HSV 1 and 2 Test to differentiate between the two causes of genital herpes infections. It will be conducted on the cobas ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announces an expanded CE mark indication for the cobas® 4800 HPV Test. The newly expanded indication for the cobas® 4800 HPV Test as a primary screen means Pap ...

Roche has announced the commercial availability of the cobas HIV-1, HCV and HCV Genotyping (GT) assays in countries accepting the CE mark. These new molecular diagnostic assays increase the available ...

- CMV viral load testing is used to assess how solid organ and hematopoietic stem cell transplant patients on therapy are responding to treatment PLEASANTON, California, June 21, 2017 /PRNewswire/ -- ...